Following the completion of its acquisition of Pharmacia, Pfizer Inc. concluded that its manufacturing facility in Caguas, Puerto Rico, was no longer required in its plant network. Pfizer retained PharmaBioSource to serve as consultants and brokers to assist in the divestiture of its the Caguas plant.
The 487,000 SF plant was viewed by Pfizer and PharmaBioSource as a significant asset to a potential buyer, both because of the manufacturing capabilities of the facility and the expertise of its employees. As an additional benefit to a potential acquirer, Pfizer was willing to provide a substantial trailing supply agreement to assist the buyer with the absorption of facility costs while the acquirer moved its own products to the plant.
At the time of sale, the Caguas plant possessed the following capabilities:
At the time of the sale of the Caguas plant, the site employed 124 colleagues and was projected to generate trailing supply agreement revenues of $13.5M to Pfizer in the first full year after the close of the transaction.
To help Pfizer Inc. achieve its goal of divesting the Caguas plant, PharmaBioSource engaged with Pfizer in the development of the marketing strategy, a target list of prospective buyers and an assessment of the type of value proposition that would attract interest from the types of companies that Pfizer was seeking as potential buyers.
PharmaBioSource utilized its extensive experience in consulting and advisory services to partner with Pfizer, with the outcome being the successful sale of the facility to Neolpharma, a respected Mexican generic drug manufacturer.
Services provided by the PharmaBioSource team:
Although the process took in excess of 18 months to complete, Pfizer was able to complete the transaction with a company that was committed to the future success of the site and its employees and one that provided Pfizer with the necessary level of comfort that its trailing supply needs would be fulfilled in a high quality, timely and cost-effective manner.
Sagent Pharmaceuticals, Inc. retained the experts at PharmaBioSource to serve as M&A consultants and advisors to assist in the divestiture of its Chinese-owned subsidiary.
Sagent (China) Pharmaceuticals, Co. Ltd., or Project Renaissance, represented a significant and potentially lucrative investment on the part of the acquiring party.
Project Renaissance involved the marketing and sale of an injectable manufacturing and development company located in Chengdu, China. With over 180 employees in a new, $100M 170,000 SF FDA-licensed aseptic facility, Project Renaissance was able to focus on high-potency products and generic injectables aimed at the U.S. market.
To help Sagent Pharmaceuticals, Inc. achieve their goal of divesting the Chinese subsidiary, PharmaBioSource went to work reviewing the business structure and site capability to develop a value proposition and place the property in front of the right parties.
We utilized the full gamut of our M&A consulting and advisory services to make the perfect match for Project Renaissance, without shortcuts.
Services provided by the PharmaBioSource team:
Within 8 short months of the initial engagement, Project Renaissance was acquired by Nanjing King-friend with an additional multi-million dollar, multi-year supply agreement included as part of the Project Renaissance deal.
3P Biopharmaceuticals engaged the experts at PharmaBioSource, Inc. as consultants and advisors to raise 6M Euros to support the growth of the company.
3P Bio is a biologics API contract manufacturing organization (CMO) located in Pamplona, Spain. 3P Bio was seeking funding to support the expansion of its mammalian cell culture and microbial fermentation development capabilities and reactor capacity within its 50,000 SF facility.
To assist 3P Bio with its goal of raising financing to support its capital requirements, PharmaBioSource engaged the biologics contract manufacturing and healthcare investment communities to identify an appropriate partner.
We utilized our expertise and extensive contacts within the biologics CMO and Life Sciences Industry to identify a number of potential partners for 3P Bio.
Services provided by the PharmaBioSource team:
PharmaBioSource, Inc. identified Infarco, the parent company of Cinfa and one of Spain’s largest generic pharmaceutical companies, as the investment partner for 3P Bio. Cinfa invested 6M Euros through a joint venture with 3P Bio to develop biosimilar products.